SCHEMBL24252331

SCHEMBL24252331

COc1ccc(CNc2nncc3cc(Br)cc(F)c23)c(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 14/20 0.45
CYP3A4 P08684 14/20 0.45
CYP2C19 P33261 14/20 0.45
CYP2D6 P10635 13/20 0.45
TSHR P16473 11/20 0.45
HSD17B10 Q99714 5/20 0.45
LMNA P02545 4/20 0.45
MAPT P10636 3/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CYP2C9 P11712 6/20 0.44
ALDH1A1 P00352 5/20 0.44
MAPK1 P28482 1/20 0.44
APLNR P35414 1/20 0.44
HIF1A Q16665 2/20 0.44
BCDIN3D Q7Z5W3 1/20 0.43
ALOX15 P16050 4/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
TDP1 Q9NUW8 1/20 0.43
USP2 O75604 5/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25217123 0.82 KDM4C (0.44) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL30451963 0.82 CYP1A2 (0.45) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL24252792 0.82 CYP1A2 (0.45) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL24252397 0.81 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL30451683 0.81 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL21551236 0.80 CYP1A2 (0.52) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL31123781 0.74 CYP1A2 (0.49) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL21682074 0.74 CYP1A2 (0.49) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL24493061 0.73 MAPT (0.52) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL30578194 0.73 MAPT (0.52) CYP1A2CYP3A4CYP2C19CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 CYP1A2 2977/4885CYP3A4 2694/4885CYP2C19 1687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.